Clinical characteristics | |
---|---|
Follow-up, mo | |
Mean (SD) | 56.5 (27.7) |
Median (min–max) | 50 (3–146) |
Age, yy | |
Mean (SD) | 71.9 (5.7) |
Median (min–max) | 73 (51–88) |
PSA, ng/mL | |
Mean (SD) | 12.93 (30.96) |
Median (min–max) | 7.70 (1.14–680) |
T staging, no (%) | |
cT1 | 355 (63%) |
cT2 | 182 (33%) |
cT3-4 | 24 (4%) |
bGS, no (%) | |
≤ 6 | 220 (39%) |
3 + 4 | 174 (31%) |
4 + 3 | 69 (12%) |
8 | 55 (10%) |
9–10 | 43 (8%) |
Biopsy cores sampled, no | |
Mean (SD) | 11.0 (4.6) |
Median (min–max) | 10 (2–35) |
%PC, % | |
Mean (SD) | 41.3% (27.8) |
Median (min–max) | 38% (4–100) |
N staging, % | |
Not performed | 72% |
performed N0 | 27.3% |
performed N1 | 0.7% |
M staging, % | |
Not performed | 74% |
performed M0 | 26% |
D’Amico risk class, no (%) | |
Low | 119 (21%) |
Intermediate | 223 (40%) |
High | 219 (39%) |
Candiolo risk class, no (%) | |
Very-low | 133 (24%) |
Low | 211 (37%) |
Intermediate | 133 (24%) |
High | 56 (10%) |
Very-high | 28 (5%) |
RT dose to prostate-CTV, ED2Gy, α/β = 2,5 | |
Mean (SD) | 77.7 (2.4) |
Median (min–max) | 78 (72–82) |
Fractionation schedule, % | |
Std fractionation 2 Gy /fr | 77% |
Hypo-fractionation 2,7 Gy /fr | 23% |
RT technique, % | |
3DCRT | 77% |
IMRT-IGRT | 23% |
Seminal vesicles irradiation, % | |
No | 22% |
Yes | 78% |
Pelvic nodal irradiation, % | |
No | 98% |
Yes | 2% |
Exclusive RT | 24% |
RT + ADT | 76% |
ADT duration, mo | |
Mean (SD) | 13.0 (10.1) |
Median (min–max) | 8 (1–46) |
ADT drug, % | |
Anti-Androgen | 37% |
LHRH-analogue | 49% |
TAB | 14% |